Inclusion Criteria:

• BMI ≥ 18 and ≤ 23 kg/m2
• Able to provide written informed consent
• Routine clinical laboratory tests either within normal limits or not clinically meaningful if outside of normal limits
• AST, ALT, Tbili within normal limits at screening
• Medical and psychiatric history and physical examination devoid of any significant findings that would interfere with participation or interpretation of results in this study
• Agree to use a barrier method of birth control for 28 days following the last dose of study medication
• Have maintained a stable weight for at least 6 months prior to Screening

Exclusion Criteria:

• Prior or current history of any psychiatric disorder, including eating disorders such as anorexia nervosa, bulimia nervosa, or binge-eating disorder
• Positive urine drug screen for any drug of abuse (including amphetamines, cannabinoids, barbiturates, cocaine, opiates, benzodiazepines) unless prescribed by a physician
• Participation in a clinical investigation of any drug, biological or other investigational therapy within 30 days prior to dosing
• Have a history of an allergic reaction to either mifepristone or risperidone
• Any other clinically significant abnormality on screening laboratory tests
• QTc Bazzett's ≥ 450 msec
• History of or current major medical condition, which in the opinion of the Investigator would place the patient at undue risk.
• Receiving any prescription or over-the-counter medications that could potentially affect appetite or weight
• Any history of a movement disorder such as Tardive Dyskinesia, Parkinsonism
• Any personal or family history of Neuroleptic Malignant Syndrome